[Contraception in diabetic women].
The choice of a contraceptive method for diabetic women must take into account metabolic and vascular risks. Combined oestrogen-progestogen contraception is not contra-indicated in insulin-dependent diabetes but requires close supervision. Progestogens alone for nulliparous women and mechanical devices for multiparous women appear to be preferable. Oral contraceptives have a more limited use in insulin-independent overt or chemical diabetes. In such patients combined oestrogen-progestogen contraception is absolutely contra-indicated and progestogens should be given under strict metabolic monitoring. The potential risks incurred by these women already liable to vascular and metabolic complications make male contraception even more desirable.
D000328:Adult; D050260:Carbohydrate Metabolism; D003267:Contraception / Q000379:methods*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects; D003920:Diabetes Mellitus / Q000378:metabolism; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007434:Intrauterine Devices / Q000009:adverse effects; D050356:Lipid Metabolism; D045167:Progesterone Congeners / Q000008:administration & dosage
D003277:Contraceptives, Oral, Combined; D007328:Insulin; D045167:Progesterone Congeners
Contraception chez la diabétique.